Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma

Liver cancer is the fourth most common cause of cancer‐related death worldwide, with hepatocellular carcinoma (HCC) being the main primary malignancy affecting the liver. Unfortunately, there are still limited therapeutic options for HCC, and even the latest advances have only increased the overall...

Full description

Bibliographic Details
Main Authors: Antonio Mulero‐Sánchez, Christel F. A. Ramirez, Aimée duChatinier, Hui Wang, Sofie J. I. Koomen, Ji‐Ying Song, Marnix H. P. deGroot, Cor Lieftink, Astrid Bosma, Artur Burylo, Olaf vanTellingen, Roderick L. Beijersbergen, Cun Wang, Leila Akkari, René Bernards, Sara Mainardi
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Molecular Oncology
Subjects:
combination
hepatocellular carcinoma
mTOR
receptor tyrosine kinases
SHP2
therapy
Online Access:https://doi.org/10.1002/1878-0261.13377

Internet

https://doi.org/10.1002/1878-0261.13377

Similar Items